Most GI side effects peak during dose escalation phases and improve within 2 to 4 weeks at a stable dose
These novel treatments aim to not only help patients shed excess weight but also improve metabolic health, reducing the risk of obesity-related conditions like diabetes and cardiovascular disease
Of the employers that said their health plan offerings do not cover GLP-1s for weight loss, a majority said they were not likely to begin covering GLP-1s for weight loss within the next 12 months (and only 1% said they were very likely to do so)
Both TNF- and IL-6 can reduce the expression of intracellular glucose transporter 4 (GLUT4), inhibit normal phosphorylation of insulin receptors and insulin receptor substrate 1 (IRS-1), block GLUT4 translocation, and lead to IR
In one study combining a certain GLP-1 medication with behavioral modifications, more than half of the participants lost 15% of their body weight, and about a third lost 20%